Cargando…
Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biolog...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705736/ https://www.ncbi.nlm.nih.gov/pubmed/34960217 http://dx.doi.org/10.3390/vaccines9121471 |
_version_ | 1784622020443504640 |
---|---|
author | Shehab, Mohammad Alrashed, Fatema Alfadhli, Ahmad Alotaibi, Khazna Alsahli, Abdullah Mohammad, Hussain Cherian, Preethi Al-Khairi, Irina Alphonse Thanaraj, Thangavel Channanath, Arshad Ali, Hamad Abu-Farha, Mohamed Abubaker, Jehad Al-Mulla, Fahd |
author_facet | Shehab, Mohammad Alrashed, Fatema Alfadhli, Ahmad Alotaibi, Khazna Alsahli, Abdullah Mohammad, Hussain Cherian, Preethi Al-Khairi, Irina Alphonse Thanaraj, Thangavel Channanath, Arshad Ali, Hamad Abu-Farha, Mohamed Abubaker, Jehad Al-Mulla, Fahd |
author_sort | Shehab, Mohammad |
collection | PubMed |
description | Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. Methods: We performed a multi-center prospective study between 1 August 2021 and 15 September 2021. We measured the seropositivity of SARS-CoV-2 antibodies (SARS-CoV-2 IgG) and neutralizing antibody concentrations in patients with IBD receiving biologic therapies 4–10 weeks after their second dose or 3–6 weeks after their first dose of BNT162b2 or ChAdOx1 nCoV-19 vaccines. Results: A total of 126 patients were enrolled (mean age, 31 years; 60% male; 71% Crohn’s disease, 29% ulcerative colitis). Of these, 92 patients were vaccinated with the BNT162b2 vaccine (73%) and 34 patients with the ChAdOx1 nCoV-19 vaccine (27%). In patients being treated with infliximab and adalimumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. In contrast, of those receiving ustekinumab and vedolizumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. On the other hand, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab, respectively. Conclusions: The majority of patients with IBD who were on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. The BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines are both likely to be effective after two doses in patients with IBD on biologics. Larger follow-up studies are needed to evaluate if decay of antibodies occurs over time. |
format | Online Article Text |
id | pubmed-8705736 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87057362021-12-25 Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies Shehab, Mohammad Alrashed, Fatema Alfadhli, Ahmad Alotaibi, Khazna Alsahli, Abdullah Mohammad, Hussain Cherian, Preethi Al-Khairi, Irina Alphonse Thanaraj, Thangavel Channanath, Arshad Ali, Hamad Abu-Farha, Mohamed Abubaker, Jehad Al-Mulla, Fahd Vaccines (Basel) Article Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. Methods: We performed a multi-center prospective study between 1 August 2021 and 15 September 2021. We measured the seropositivity of SARS-CoV-2 antibodies (SARS-CoV-2 IgG) and neutralizing antibody concentrations in patients with IBD receiving biologic therapies 4–10 weeks after their second dose or 3–6 weeks after their first dose of BNT162b2 or ChAdOx1 nCoV-19 vaccines. Results: A total of 126 patients were enrolled (mean age, 31 years; 60% male; 71% Crohn’s disease, 29% ulcerative colitis). Of these, 92 patients were vaccinated with the BNT162b2 vaccine (73%) and 34 patients with the ChAdOx1 nCoV-19 vaccine (27%). In patients being treated with infliximab and adalimumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. In contrast, of those receiving ustekinumab and vedolizumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. On the other hand, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab, respectively. Conclusions: The majority of patients with IBD who were on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. The BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines are both likely to be effective after two doses in patients with IBD on biologics. Larger follow-up studies are needed to evaluate if decay of antibodies occurs over time. MDPI 2021-12-13 /pmc/articles/PMC8705736/ /pubmed/34960217 http://dx.doi.org/10.3390/vaccines9121471 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shehab, Mohammad Alrashed, Fatema Alfadhli, Ahmad Alotaibi, Khazna Alsahli, Abdullah Mohammad, Hussain Cherian, Preethi Al-Khairi, Irina Alphonse Thanaraj, Thangavel Channanath, Arshad Ali, Hamad Abu-Farha, Mohamed Abubaker, Jehad Al-Mulla, Fahd Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
title | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
title_full | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
title_fullStr | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
title_full_unstemmed | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
title_short | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
title_sort | serological response to bnt162b2 and chadox1 ncov-19 vaccines in patients with inflammatory bowel disease on biologic therapies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705736/ https://www.ncbi.nlm.nih.gov/pubmed/34960217 http://dx.doi.org/10.3390/vaccines9121471 |
work_keys_str_mv | AT shehabmohammad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT alrashedfatema serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT alfadhliahmad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT alotaibikhazna serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT alsahliabdullah serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT mohammadhussain serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT cherianpreethi serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT alkhairiirina serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT alphonsethanarajthangavel serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT channanatharshad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT alihamad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT abufarhamohamed serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT abubakerjehad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT almullafahd serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies |